Elvitegravir + Elvitegravir%2C Cobicistat%2C Emtricitabine%2C And Tenofovir Disoproxil Fumarate Interaction
Unknowninteraction on record
Description
Elvitegravir is a modest inducer of CYP2C9 and may decrease the plasma concentrations of CYP2C9 substrates. 7.3 Potential for Other Drugs to Affect One or More Components of STRIBILD Elvitegravir and cobicistat, components of STRIBILD, are metabolized by CYP3A. Drugs that induce CYP3A activity are expected to increase the clearance of elvitegravir and cobicistat, resulting in decreased plasma concentration of cobicistat and elvitegravir, which may lead to loss of therapeutic effect of STRIBILD and development of resistance (Table 5).
Source: FDA drug label - elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate